Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-human, Open-label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-253 in Adult Subjects With Advanced Solid Tumors

NCT07807956 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07807956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07807956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-human, Open-label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-253 in Adult Subjects With Advanced Solid Tumors
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
December 31, 2029
Enrollment
130 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, biliary tract cancer, colorectal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer, ovarian cancer, pancreatic ductal adenocarcinoma